Navigation Links
Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Date:10/5/2007

FRANKLIN, Mass., Oct. 5 /PRNewswire-FirstCall/ -- Following its recent merger with Echo Therapeutics, Inc., Sontra Medical Corporation (OTC Bulletin Board: SONT), a dual platform-enabled transdermal specialty therapeutics and diagnostics company, today announced that it has changed its corporate name to Echo Therapeutics, Inc., effective Monday, October 8, 2007. In addition, on October 8, 2007, the Company's OTC Bulletin Board ticker symbol will change to "ECTE" and its corporate website address will become http://www.echotx.com.

"Our new name better reflects our expanded strategic focus on building a broad pipeline of advanced topical formulations of FDA-approved specialty pharmaceutical products and next generation needle-free transdermal diagnostics," said Patrick T. Mooney, M.D., CEO of Echo Therapeutics.

About Echo Therapeutics

Echo Therapeutics is a dual platform-enabled, specialty therapeutics and diagnostics company developing an extensive pipeline of advanced topical formulations of FDA-approved products and a suite of needle-free transdermal diagnostics. Echo is developing a next generation, needle-free Continuous Transdermal Glucose Monitor (CTGM) system for use in the diabetes home care and hospital critical care markets. Echo's next generation CTGM system leverages its FDA-approved SonoPrep(R) ultrasound-mediated skin permeation technology platform. Echo is also developing a broad portfolio of advanced topical formulations of well-established, FDA-approved products using its proprietary AzoneTS(TM) dermal penetration technology. Echo has submitted a New Drug Application (NDA) to the FDA for the approval of its lead Azone TS- based product, Durhalieve(TM), for the treatment of corticosteroid responsive dermatoses.

SonoPrep is a registered trademark of Echo Therapeutics, Inc.

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward- looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to our ability to develop, market and sell pharmaceutical or diagnostic products based on our AzoneTS and SonoPrep platform technologies, including AzoneTS-based Durhalieve for corticosteroid responsive dermatoses and a SonoPrep-based continuous transdermal glucose monitor system for the diabetes and hospital critical care markets; the availability of substantial additional equity capital to support our robust research, development and product commercialization activities; and the success of our AzoneTS and SonoPrep business, research, development, and regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-KSB for the year ended December 31, 2006, our most recent quarterly reports on Form 10-QSB, and our current reports on Form 8-K. Echo Therapeutics, Inc. does not undertake to update these forward-looking statements.

10 Forge Parkway

Franklin, MA 02038, USA

Tel: 1+ 877-4-SONTRA (766878)

Fax: 1+ 508-553-8760

http://www.echotx.com

Investor Relations Contacts:

Patrick T. Mooney, M.D., CEO

508-530-0329

pmooney@echotx.com


'/>"/>
SOURCE Echo Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Check if your “Favourite medical web-site” is indulging in Quackey
2. Teens turning to Internet for medical queries
3. Robots craft medical history
4. NBE to conduct test for medical students from abroad
5. Air pollution combined with greater medical needs
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Children! Protecting them from medical mistakes
8. More information sought by patients on medical errors
9. SARS necessitates medical masks
10. Meditation Works Medically
11. Sleep Disorders Could Indicate Other Medical Problems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2016)... ... May 29, 2016 , ... Whole Health Supply is happy ... that has been available via Amazon.com. This new style of nail clipper has a ... jaw opening is approximately 4mm and the actual handle is 2.5mm thick to accommodate ...
(Date:5/29/2016)... ... 2016 , ... "With 30 unique self-animating web themed intros and complete control ... project," said Christina Austin - CEO of Pixel Film Studios. , ProIntro Web ... in Final Cut Pro X. Pixel Film Studios’ minimalistic titles allow users to add ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can ... drop a preset onto their media," said Christina Austin - CEO of Pixel Film ... can quickly and easily add stylish color grades to their footage. A LUT is ...
(Date:5/28/2016)... ... ... year and a half of planning the Multiple Pathways of Recovery Conference , CCAR ... Conference was held May 2 -4, 2016 at the Mystic Marriott Hotel & Spa ... the many pathways individuals use to get into and sustain their recovery. Pathways of ...
(Date:5/27/2016)... ... May 27, 2016 , ... More than a third of ... not surprising that bariatric surgery has received increased attention in recent years, as an ... when it comes to weight loss, most people are familiar with the basic requirements ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Deutschland und GERMANTOWN, Maryland , ... Zusammenarbeit mit Therawis bedient dringenden ...   QIAGEN N.V. (NASDAQ: ... bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics ... die Onkologie eingegangen zu sein. Ein erstes Projekt ...
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... 25, 2016 MedDay, a biotechnology company ... an oral presentation entitled "High doses of biotin in progressive ... be given by Professor Ayman Tourbah , Principal Investigator ... the European Academy of Neurology (EAN) in Copenhagen, ... 3" will take place on Sunday, 29 May 2016 from ...
Breaking Medicine Technology: